New pre-chemotherapy treatment options for CRPC — YRD

New pre-chemotherapy treatment options for CRPC (#27)

Peter Fong 1
  1. Auckland Hospital, Grafton, Graft, New Zealand
The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed significantly within the last 4 years with at least 5 newly approved drugs. These range from cytotoxics to immunotherapy to novel hormonal agents and bone targeting monoclonal antibodies. Many of the treatments have proven survival benefit especially in the post-docetaxel setting. Unfortunately there is no validated biomarker to determine response, to guide selection of drugs and sequencing although we hope this will change as we enter the precision medicine era. Clinical assessment and an individualised approach remains important. The treatment paradigm is now shifting and pre- or post- docetaxel use may no longer be an appropriate algorithm. These agents are also edging towards the non-metastatic CRPC arena, metastatic hormone sensitive disease and neoadjuvant therapy.